基于mRNA的尿液检测用于膀胱癌监测的前瞻性验证
该研究前瞻性收集22个中心有非肌层浸润性膀胱癌病史患者的膀胱镜前尿液,验证Xpert膀胱癌监测检测(测量ABL1、CRH、IGF2、UPK1B、ANXA10五种mRNA)的特性。
要点
- Xpert尿液检测对膀胱癌复发总体敏感性74%,高级别肿瘤敏感性83%。
- Xpert总体阴性预测值93%,高级别肿瘤阴性预测值98%,优于尿细胞学和UroVysion。
- Xpert特异性80%,在无膀胱癌病史人群中特异性95%。
核心结论
- 在膀胱癌随访患者中,Xpert的阴性预测值优于UroVysion和尿细胞学,是有望排除膀胱癌、减少膀胱镜需要的工具。
研究设计与样本
- 前瞻性研究,在22个中心收集膀胱镜前排尿尿液样本,对既往诊断为非肌层浸润性膀胱癌的患者进行Xpert、尿细胞学和UroVysion检测。
- 239例有膀胱癌病史的合格患者纳入分析,平均年龄71岁,190例男性,53例从不吸烟,64%既往接受过膀胱内免疫治疗(35%)或化疗(29%)。
- 另在508例无膀胱癌病史或临床证据的患者中测定特异性,并进行技术验证。
主要发现
- Xpert总体敏感性74%(95%CI:60-85),高级别肿瘤敏感性83%(95%CI:64-93)。
- Xpert总体阴性预测值93%(95%CI:89-96),高级别肿瘤阴性预测值98%(95%CI:94-99)。
- Xpert特异性80%(95%CI:73-85);在无膀胱癌个体(n=508)中特异性95%(95%CI:93-97)。
- Xpert的敏感性和阴性预测值优于尿细胞学和UroVysion。
临床怎么用
- Xpert可作为膀胱癌随访中排除复发的尿液检测工具,可能减少膀胱镜的需要。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A fast, noninvasive test with high sensitivity (SN) and a negative predictive value (NPV), which is able to detect recurrences in bladder cancer (BC) patients, is needed. A newly developed urine assay, Xpert Bladder Cancer Monitor (Xpert), measures five mRNA targets (ABL1, CRH, IGF2, UPK1B, and ANXA10) that are frequently overexpressed in BC. OBJECTIVE: To validate Xpert characteristics in patients previously diagnosed with non-muscle-invasive BC. DESIGN, SETTING, AND PARTICIPANTS: Voided precystoscopy urine samples were prospectively collected at 22 sites. Xpert, cytology, and UroVysion were performed. If cystoscopy was suspicious for BC, a histologic examination was performed. Additionally, technical validation was performed and specificity was determined in patients without a history or clinical evidence of BC. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Test characteristics were calculated based on cystoscopy and histology results, and compared between Xpert, cytology, and UroVysion. RESULTS AND LIMITATIONS: Of the eligible patients, 239 with a history of BC had results for all assays. The mean age was 71 yr; 190 patients were male, 53 never smoked, and 64% had previous intravesical immunotherapy (35%) or chemotherapy (29%). Forty-three cases of recurrences occurred. Xpert had overall SN of 74% (95% confidence interval [CI]: 60-85) and 83% (95% CI: 64-93) for high-grade (HG) tumors. The NPV was 93% (95% CI: 89-96) overall and 98% (95% CI: 94-99) for HG tumors. Specificity was 80% (95% CI: 73-85). Xpert SN and NPV were superior to those of cytology and UroVysion. Specificity in non-BC individuals (n=508) was 95% (95% CI: 93-97). CONCLUSIONS: Xpert has an improved NPV compared with UroVysion and cytology in patients under follow-up for BC. It represents a promising tool for excluding BC in these patients, reducing the need for cystoscopy. PATIENT SUMMARY: Xpert is an easy-to-perform urine test with good performance compared with standard urine tests. It should help optimize the follow-up of recurrent bladder cancer patients.
引用
- Valenberg FJPV, Hiar AM, Wallace E, et al. Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer. Eur Urol. 2018. PMID: 30553612. doi:10.1016/j.eururo.2018.11.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。